TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06513052

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Commercial cocoa
Description: daily intake of a beverage made with 8 grams of commercial cocoa low in flavanols, dissolved in 200 mL of low-fat, lactose-free milk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flavonols Cocoa
Description: Daily intake of a beverage made with 8 grams of cocoa high in flavanols, dissolved in 200 mL of low-fat, lactose-free milk.
Study: NCT05934695

Intervention type: OTHER
Intervention: Lymphedema severity stratification
Description: Participants will be stratified into one of three lymphedema severity groups based on the International Society of Lymphology lymphedema severity staging:~Mild (stage 1): swelling with pitting; normal skin and tissue turgor Moderate (stage 2): swelling with pitting; dermal thickening; skin changes without distortional warty-overgrowth Severe (stage 3): swelling with non-pitting; warty overgrowth or elephantiasis folds

Intervention type: OTHER
Intervention: Lymphedema severity stratification
Description: Participants will be stratified into one of three lymphedema severity groups based on the International Society of Lymphology lymphedema severity staging:~Mild (stage 1): swelling with pitting; normal skin and tissue turgor Moderate (stage 2): swelling with pitting; dermal thickening; skin changes without distortional warty-overgrowth Severe (stage 3): swelling with non-pitting; warty overgrowth or elephantiasis folds

Intervention type: OTHER
Intervention: Lymphedema severity stratification
Description: Participants will be stratified into one of three lymphedema severity groups based on the International Society of Lymphology lymphedema severity staging:~Mild (stage 1): swelling with pitting; normal skin and tissue turgor Moderate (stage 2): swelling with pitting; dermal thickening; skin changes without distortional warty-overgrowth Severe (stage 3): swelling with non-pitting; warty overgrowth or elephantiasis folds
Study: NCT05920447

Intervention type: DEVICE
Intervention: LMA
Description: Monitor the ventilatory parameter and incidence of complications
Study: NCT06520904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: PCSK9 inhibitors combined with moderate-intensity statin therapy

Intervention type: DRUG
Group type: OTHER
Intervention: Statin
Description: Intensive statin therapy
Study: NCT05850676

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep study
Description: Participants will spend two nights in the Penn Sleep Center

Intervention type: DIAGNOSTIC_TEST
Intervention: Sleep study
Description: Participants will spend two nights in the Penn Sleep Center
Study: NCT05293106

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion
Description: All platelet transfusions will be given as 10mL/kg as is considered standard of care.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Transfusion
Description: All platelet transfusions will be given as 10mL/kg as is considered standard of care.
Study: NCT04951778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-91633
Description: Administered orally according to the assigned treatment schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-91633
Description: Administered orally according to the assigned treatment schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-91633
Description: Administered orally according to the assigned treatment schedule
Study: NCT04810572

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Composition with Silymarin
Description: Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Composition with Silymarin
Description: Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Composition with Silymarin
Description: Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-mineral composition without Silymarin
Description: Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-mineral composition without Silymarin
Description: Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-mineral composition without Silymarin
Description: Volunteers will receive supplementation for 180 days. They took 4 capsules daily. Two capsules in the morning and two capsules at night.~There will be blood and feces collection at zero time, before supplementation, after 30, 90 and 180 days from the beginning of supplementation.
Study: NCT06178328

Intervention type: BEHAVIORAL
Intervention: Things You Do Course
Description: Participants receiving the brief psychological intervention ('Things You Do' Course) will have access to a single online lesson that includes course materials and printable materials (i.e., an activity guide and planner) that can be retained for longer-term use. The course materials include an introduction to the purpose and content of the course, education about factors that impact mental health, and information about the 'Big Five' things participants can do to improve their mental health. Participants will also receive automated no-reply emails (5 days/week) through the intervention platform to remind them to practice the skills from the course.
Study: NCT05377424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Oxygen therapy
Description: Breathing short periods of low oxygen, consisting of 15 episodes of 1 minute of breathing 10% oxygen, with 2 minutes of breathing 21% oxygen. 45 minutes total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Oxygen therapy
Description: Breathing short periods of low oxygen, consisting of 15 episodes of 1 minute of breathing 10% oxygen, with 2 minutes of breathing 21% oxygen. 45 minutes total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo counterpart to the istradefylline drug
Description: Consume a single microcrystalline cellulose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo counterpart to the istradefylline drug
Description: Consume a single microcrystalline cellulose

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHAM counterpart to low oxygen therapy.
Description: Breathing short periods of sham low oxygen, consisting of 15 episodes of 1 minute of breathing 21% oxygen, separated by 2 minutes of breathing 21% oxygen. 45 minutes total.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SHAM counterpart to low oxygen therapy.
Description: Breathing short periods of sham low oxygen, consisting of 15 episodes of 1 minute of breathing 21% oxygen, separated by 2 minutes of breathing 21% oxygen. 45 minutes total.
Study: NCT04991454

Intervention type: DRUG
Group type: OTHER
Intervention: 129Xe Hyperpolarized
Description: Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.

Intervention type: DRUG
Group type: OTHER
Intervention: 129Xe Hyperpolarized
Description: Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC), as is the case for all protocols currently carried out under IND 109,490.
Study: NCT06522568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyMammogram
Description: An online breast cancer screening decision aid

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MyMammogram
Description: An online breast cancer screening decision aid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider communication
Description: Provider will be provided with information from MyMammogram that includes patient's breast cancer risk and preferences for mammograms prior to the appointment
Study: NCT06378190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells therapy
Description: CAR-T cells therapy
Study: NCT05238116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC945
Description: Sterile aqueous liquid for Nebulization
Study: NCT05813093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Accelerated iTBS treatment
Study: NCT05238116

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile aqueous liquid for Nebulization
Study: NCT06088303

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjunctive writing to amplify response and engagement (AWARE)
Description: AWARE includes two components: 1) patients complete brief writing prompts asking about their experiences in treatment, and 2) therapists review patients' responses and facilitate guided discussion related to patients' experiences during check-ins at the beginning of each session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive processing therapy (CPT)
Description: CPT is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 60-minute sessions. CPT focuses on helping patients identify trauma-related stuck points (inaccurate and/or unhelpful beliefs) and challenge those beliefs to arrive at healthier, more balanced beliefs about their traumatic experiences, themselves, others, and the world.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (CPT)
Description: CPT is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 60-minute sessions. CPT focuses on helping patients identify trauma-related stuck points (inaccurate and/or unhelpful beliefs) and challenge those beliefs to arrive at healthier, more balanced beliefs about their traumatic experiences, themselves, others, and the world.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged exposure (PE)
Description: PE is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 90-minute sessions. PE focuses on reducing unhelpful avoidance and helping patients process and make sense of their traumatic experiences through in vivo and imaginal exposure to trauma-related reminders and memories.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged exposure (PE)
Description: PE is a manualized, evidence-based therapy for PTSD typically delivered over the course of 8-15 weekly 90-minute sessions. PE focuses on reducing unhelpful avoidance and helping patients process and make sense of their traumatic experiences through in vivo and imaginal exposure to trauma-related reminders and memories.
Study: NCT06458387

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active protein supplementation
Description: The participants in active nutritional supplementation arm received consultation from the nutritional support team (NST) upon ICU admission, and nutritional supplementation was initiated on the same day. NST is a multidisciplinary support team comprised of physicians, nurses, dietitians, and pharmacists, which assesses the nutritional status of patients, and provides recommendations for nutritional therapy. Targets in the participants in active protein supplementation arm were protein supplementation at over 1.5 g/kg/day during first 3 days after ICU admission. Actual body weight was used as the body weight for patients with a percent of ideal body weight (PIBW) of less than 120%, while adjusted body weight was used for patients with a PIBW greater than or equal to 120%.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Conventional protein supplementation
Description: The participants in conventional protein supplementation arm received conservative nutritional management without specific protein targets.
Study: NCT06529250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAD
Description: Induction therapy:Homoharringtonine: 2mg/㎡/d, days 1-7 Cytarabine: (Ara-c 100mg/㎡/d, day 1-4; 1g/㎡ /q12h, day 5-7), Daunorubicin: (DNR 40mg/㎡/d, day 1-3).~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ for d1-3 , Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5) . Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin+Cytarabine
Description: Cytarabine: (Ara-c 100mg/㎡/d, day 1-7), Daunorubicin: (DNR 60mg/㎡/d, day 1-3) or idarubicin (IDA 12mg/㎡/d, day 1-3).~Treatment did not achieve CR, and reinduction of IAC regimen was given.~Reinduction therapy:~Idarubicin (IDA) 10mg/㎡ ,d1-3, Ara-c 100mg/㎡ d1-7 , Cyclophosphamide (CTX350mg/㎡ d2, d5). Patients who did not achieve CR after reinduction therapy were removed from the group.~After achieving CR, they received high-dose cytarabine (3g/m2 q12h, 3 days) regimen for consolidation for 3 courses. Hematopoietic stem cell transplantation is recommended for patients with persistent MRD positive after treatment.
Study: NCT06179290

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ploom HTP Menthol HTS; MX3 (681)
Description: Menthol heated tobacco product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ploom HTP Tobacco HTS; R8 (120)
Description: Non-menthol heated tobacco product

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence (menthol)
Description: No smoking or other tobacco product use for duration of the study, menthol group comparator

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Abstinence (non-menthol)
Description: No smoking or other tobacco product use for duration of the study, non-menthol group comparator
Study: NCT06550050

Intervention type: BEHAVIORAL
Intervention: Radiation
Description: Standard of care
Study: NCT05687760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bromelain
Description: is a proteolytic enzyme derived from the stem part and fruit of pineapples (Ananas comosus).used as intracanal medication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: calcium hydroxide
Study: NCT05533242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu-177 labeled 6A10-Fab-fragments
Description: The antibody 6A10 is a specific CA12 Inhibitor, a highly specific glioma cell-associated enzyme; all tumor cells are CA12-positive, while its expression in normal brain is very low, and Lu-177 has a comparable β-emission, but a significantly low γ-Emission.
Study: NCT04344860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Von Willebrand factor
Description: Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Von Willebrand factor
Description: Recombinant Von Willebrand factor(Vonvendi) is an intravenous therapy that replaces missing VWF to restore hemostasis and reduce bleeding with surgery or delivery.
Study: NCT05561179

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid injection
Description: Patients with confirmed diagnosis of GERD will be treated with HA injections in the lower esophageal portion. HA + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sodium chloride injection (control group)
Description: Patients with a confirmed diagnosis of GERD will be treated with sodium chloride injection in the lower esophageal portion. Sodium chloride + contrast will be injected in the 4 quadrants (4 cc/quadrant).~The response to the treatment will be measured by improvement in health-related quality of life index, pH monitoring, and endoluminal functional lumen imaging probe (EndoFLIP). In addition, the patients will be clinically assessed for reflux symptoms.
Study: NCT04817527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edaravone Dexborneol
Description: Intravenous injections of edaravone dexborneol (37.5mg in 0·9% NaCl) BID for 7-14days.
Study: NCT06181279

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized PEEP group
Description: Individualized PEEP group: Recruitment Maneuver (RM) is performed first. In pressure control mode, PEEP and airway plateau pressure are increased to 20 cmH2O and 35 cmH2O at a rate of 5 cmH2O every 30s, and driving pressure is maintained at 15 cmH2O throughout. Subsequently, in volume-controlled ventilation mode, PEEP decreases from 20 cmH2O to 4 cmH2O at gradient of 2 cmH2O, and each PEEP level is maintained for 30s. The PEEP corresponding to the lowest driving pressure is the individualized PEEP we need. If multiple PEEP levels showed the same lowest driving pressure, the lowest PEEP value as the individualized PEEP. The above procedures are performed three times during the surgery (5 minutes after intubation,5 minutes after the beginning of pneumoperitoneum, and 5 minutes after the end of pneumoperitoneum).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fixed PEEP group
Description: After the same RM, PEEP is fixed at 8 cmH2O.
Study: NCT04961970

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin , fluorouracil, and leucovorin
Description: administration of oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and cisplatin
Description: administration of gemcitabine and cisplatin via vein
Study: NCT04344860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid Injection [Cyklokapron]
Description: Tranexamic acid (Cyclokapron) is an intravenous anti-fibrinolytic therapy that prevents clot breakdown and reduces bleeding with surgery or delivery.
Study: NCT04994483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam
Description: Simufilam is a novel drug candidate designed to treat and slow the progression of AD. Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42. In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given b.i.d. for 52 weeks.
Study: NCT06404086

Intervention type: DRUG
Group type: OTHER
Intervention: Modafinil
Description: Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.~Study drug administration will total 10 weeks.
Study: NCT05012787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CpG 1018/Alum-adjuvanted SCB-2019 vaccine
Description: Participants will receive 1 intramuscular (IM) injection of 30 microgram (mcg) SCB-2019 with CpG 1018/Alum adjuvant on Day 1 and on Day 22.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Havrix
Description: Participants will receive Havrix (Hepatitis A vaccine) containing 1440 Enzyme-linked Immunosorbent Assay (ELISA) units (EL.U.) in 1.0 mL dose on Day 1.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo; 0.9% saline
Description: Participants will receive 1 IM injection of SCB-2019-matching placebo on Day 22.